Single arm phase 2 trial of atezolizumab and bevacizumab in Epidermal Growth Factor Receptor (EGFR) mutant non-small cell lu¬¬ng cancer in patients with disease progression after osimertinib"
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
May 15, 2020
End Date
January 31, 2025
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
May 15, 2020
End Date
January 31, 2025